New drug combo trial offers hope for Tough-to-Treat lung cancer
NCT ID NCT07407933
Summary
This study is testing a new drug called YL201 in combination with an existing cancer therapy (atezolizumab) for people with advanced small cell lung cancer who haven't had prior treatment. The main goals are to find a safe and effective dose and to see how well the combination works to control the cancer. About 118 participants will receive the treatment until their cancer worsens or side effects become too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THORACIC NEOPLASMS, LUNG DISEASES, SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20057, United States
Contact
Conditions
Explore the condition pages connected to this study.